AU2001249626A1 - Cathepsin inhibitors in cancer treatment - Google Patents
Cathepsin inhibitors in cancer treatmentInfo
- Publication number
- AU2001249626A1 AU2001249626A1 AU2001249626A AU4962601A AU2001249626A1 AU 2001249626 A1 AU2001249626 A1 AU 2001249626A1 AU 2001249626 A AU2001249626 A AU 2001249626A AU 4962601 A AU4962601 A AU 4962601A AU 2001249626 A1 AU2001249626 A1 AU 2001249626A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer treatment
- cathepsin inhibitors
- cathepsin
- inhibitors
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09539739 | 2000-03-31 | ||
US09/539,739 US6605589B1 (en) | 2000-03-31 | 2000-03-31 | Cathepsin inhibitors in cancer treatment |
PCT/US2001/010196 WO2001074376A2 (en) | 2000-03-31 | 2001-03-30 | Cathepsin inhibitors in cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001249626A1 true AU2001249626A1 (en) | 2001-10-15 |
Family
ID=24152451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001249626A Abandoned AU2001249626A1 (en) | 2000-03-31 | 2001-03-30 | Cathepsin inhibitors in cancer treatment |
Country Status (3)
Country | Link |
---|---|
US (2) | US6605589B1 (en) |
AU (1) | AU2001249626A1 (en) |
WO (1) | WO2001074376A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020006899A1 (en) * | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
DE19940130A1 (en) * | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | New effectors of Dipeptidyl Peptidase IV for topical use |
US6605589B1 (en) * | 2000-03-31 | 2003-08-12 | Parker Hughes Institute | Cathepsin inhibitors in cancer treatment |
US7368421B2 (en) * | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
EP1492525A2 (en) * | 2001-08-16 | 2005-01-05 | Probiodrug AG | Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
US6844316B2 (en) * | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
EP1961416B1 (en) * | 2003-05-05 | 2013-01-23 | Probiodrug AG | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. |
ATE462432T1 (en) * | 2003-05-05 | 2010-04-15 | Probiodrug Ag | GLUTAMINYL CYCLASE INHIBITORS |
EA010108B1 (en) * | 2003-10-15 | 2008-06-30 | Пробиодруг Аг | Use of effectors of glutaminyl and glutamate cyclases |
US7632972B2 (en) * | 2003-10-30 | 2009-12-15 | The Board Of Trustees Of The University Of Illionis | Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells |
BRPI0507485A (en) | 2004-02-05 | 2007-07-10 | Probiodrug Ag | new glutaminyl cyclase inhibitors |
US20090312277A1 (en) * | 2004-11-19 | 2009-12-17 | Abdelhadi Rebbaa | Compositions And Methods For Reversing Or Preventing Resistance Of A Cancer Cell To A Cytotoxic Agent |
WO2008134474A2 (en) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
CA2617600A1 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Attenuated reovirus |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
BRPI0711769A2 (en) | 2006-05-19 | 2011-12-13 | Univ Illinois | phosphorus-containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers |
US10369171B2 (en) * | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
WO2008112917A2 (en) * | 2007-03-13 | 2008-09-18 | Uti Limited Partnership | Peptidyl fluoromethylketones as inhibitors of viral replication |
WO2010091382A1 (en) | 2009-02-09 | 2010-08-12 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
JP5234550B2 (en) * | 2010-03-01 | 2013-07-10 | 独立行政法人科学技術振興機構 | VDAC function regulator |
US20160101076A1 (en) * | 2013-05-15 | 2016-04-14 | Ronald J. Weigel | Use of Sumoylation Inhibitors for Treating Cancer |
JP6899771B2 (en) * | 2014-08-12 | 2021-07-14 | ギリース・マッキンドー・リサーチ・インスティチュートGillies Mcindoe Research Institute | Diagnosis and treatment of cancer |
US10954197B2 (en) | 2017-03-08 | 2021-03-23 | Yogee's Bioinnovations Private Limited | Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer |
EP3884948A1 (en) * | 2020-03-26 | 2021-09-29 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Cathepsin inhibitors and uses thereof |
WO2024168137A1 (en) * | 2023-02-08 | 2024-08-15 | Iogenetics, Llc | Cleaved neoepitopes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496927A (en) * | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
CZ206097A3 (en) * | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Cathepsin k inhibition process |
JP3338452B2 (en) | 1995-12-12 | 2002-10-28 | 大鵬薬品工業株式会社 | Epoxysuccinamide derivatives or salts thereof and pharmaceuticals containing the same |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
JP2002539190A (en) * | 1999-03-15 | 2002-11-19 | アクシス・ファーマシューティカルズ・インコーポレイテッド | Novel compounds and compositions as protease inhibitors |
AU2135001A (en) | 1999-12-15 | 2001-06-25 | Mcgill University | Targeting of endosomal growth factor processing as anti-cancer therapy |
US6605589B1 (en) * | 2000-03-31 | 2003-08-12 | Parker Hughes Institute | Cathepsin inhibitors in cancer treatment |
-
2000
- 2000-03-31 US US09/539,739 patent/US6605589B1/en not_active Expired - Fee Related
-
2001
- 2001-03-30 AU AU2001249626A patent/AU2001249626A1/en not_active Abandoned
- 2001-03-30 WO PCT/US2001/010196 patent/WO2001074376A2/en active Application Filing
-
2003
- 2003-07-02 US US10/612,215 patent/US20040005329A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040005329A1 (en) | 2004-01-08 |
WO2001074376A3 (en) | 2002-02-07 |
US6605589B1 (en) | 2003-08-12 |
WO2001074376A2 (en) | 2001-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001249626A1 (en) | Cathepsin inhibitors in cancer treatment | |
IL251270A0 (en) | Cancer treatment | |
AU2002219472A1 (en) | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens | |
AU2002223827A1 (en) | Well treatment | |
AU2002258990A1 (en) | Improvements in ablation therapy | |
AU2002339157A1 (en) | Inhibitors of the notch signalling pathway for use in the treatment of cancer | |
PL370029A1 (en) | 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer | |
AU2001282717A1 (en) | Cancer treatment by combination therapy | |
AUPQ923100A0 (en) | Treatment of prostate cancer | |
AU2001266838A1 (en) | Inhibitors of matriptase for the treatment of cancer | |
HUP0300005A3 (en) | Modified cytokines for use in cancer therapy | |
AU2001227972A1 (en) | Methods to treat alpha-1-antitrypsin deficiency | |
AU2001236929A1 (en) | Surface treatment | |
AU2002362613A1 (en) | Galectins-1-and-4 in tumor development | |
AU2002215111A1 (en) | Ruthenium-aryl-compounds in cancer therapy | |
AU2001257325A1 (en) | Cancer treatment | |
AU2001276462A1 (en) | Use of natural products in cancer treatment | |
GB0026015D0 (en) | Cancer treatment | |
AU2001261324A1 (en) | Psoriasis treatment | |
AU2001278738A1 (en) | Medicinal compositions for preventing and treating cancer | |
AU2001282349A1 (en) | Fluid treatment | |
AU2001247922A1 (en) | Calpain inhibitors in cancer treatment | |
AU2001289127A1 (en) | Tumor treatment | |
AU2001257168A1 (en) | Cancer treatment | |
AU2002305138A1 (en) | Methods and materials for cancer treatment |